World Journal of Surgery

, Volume 38, Issue 8, pp 2132–2137

Is Perineural Invasion More Accurate Than Other Factors to Predict Early Recurrence after Pancreatoduodenectomy for Pancreatic Head Adenocarcinoma?

  • Thibaut Fouquet
  • Adeline Germain
  • Laurent Brunaud
  • Laurent Bresler
  • Ahmet Ayav
Article

Abstract

Background

Some patients operated by pancreaticoduodenectomy for resectable pancreatic head adenocarcinoma will present with a recurrence during the first year (early recurrence).

Objective

The aim of this study was to determine prognostic factors associated with early recurrence in a large retrospective study.

Methods

From January 1995 to November 2010, all patients operated by pancreaticoduodenectomy for pancreatic head adenocarcinoma in our institution were retrospectively included. Univariate and multivariate analyses were performed to determine factors associated with early recurrence.

Results

A total of 166 patients were included; 57 patients (34 %) developed early recurrence. In univariate analysis, factors associated with early recurrence were perineural invasion (p = 0.0002), preoperative bilirubin (p = 0.01), lymph node ratio (LNR) ≥0.2 (p = 0.009), and T stage (p = 0.02). In multivariate analysis, perineural invasion (odds ratio [OR] 3.31; 95 % confidence interval [CI] 1.42–7.72; p = 0.005), LNR ≥0.2 (OR 2.55; 95 % CI 1.17–5.52; p = 0.02), and preoperative bilirubin (OR 1.04; 95 % CI 1.01–1.07; p = 0.03) were independent factors associated with early recurrence. Perineural invasion was also associated with poor overall survival (p = 0.001) and poor disease-free survival (p = 0.07).

Conclusion

In our study, perineural invasion (OR 3.31) is more accurate than T stage and lymph node status (OR 2.55) to predict early recurrence after pancreatoduodenectomy for pancreatic head adenocarcinoma.

References

  1. 1.
    Trede M, Schawall G, Saeger HD (1990) Survival after pancreaticoduodenectomy. 118 Consecutive resections without an operative mortality. Ann Surg 211:447–458PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Yeo CJ, Cameron JL, Sohn TA et al (1997) Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications and outcomes. Ann Surg 226:248–257PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Nitecki SS, Sarr MG, Colby TV et al (1995) Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221:59–66PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Moreaux J, Catala M, Marzano L (1984) Results of the surgical treatment of pancreatic cancer. Study of a series of 96 surgically treated patients. Gastroenterol Clin Biol 8:11–16PubMedGoogle Scholar
  5. 5.
    Magistrelli P, Antinori A, Crucitti A et al (2000) Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol 74:36–40PubMedCrossRefGoogle Scholar
  6. 6.
    Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277PubMedCrossRefGoogle Scholar
  7. 7.
    Neoptolemos JP, Moore MJ, Cox TF et al (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308:147–156PubMedCrossRefGoogle Scholar
  8. 8.
    Kim EJ, Ben-Jospef E, Herman JM et al (2013) A multi-institutional phase 2 study of neo adjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 119:2692–2700PubMedCrossRefGoogle Scholar
  9. 9.
    Zhang Y, Adam EF, Kyriakides C et al (2012) Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemotherapy. J Cancer Res Clin Oncol 138:1063–1071PubMedCrossRefGoogle Scholar
  10. 10.
    Slidell MB, Chang DC, Cameron JL et al (2008) Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 15:165–174PubMedCrossRefGoogle Scholar
  11. 11.
    Verbeke CS, Menon KV (2009) Redefining resection margin status in pancreatic cancer. HPB (Oxf) 11:282–289CrossRefGoogle Scholar
  12. 12.
    Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and result of Survey. Ann Surg 240:205–213PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Bassi C, Dervenis C, Butturini G et al (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8–13PubMedCrossRefGoogle Scholar
  14. 14.
    Wente MN, Bassi C, Dervenis C et al (2007) Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 142:761–768PubMedCrossRefGoogle Scholar
  15. 15.
    Hartwig W, Hackert T, Hinz U et al (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254:311–319PubMedCrossRefGoogle Scholar
  16. 16.
    Helm J, Centeno BA, Coppola D et al (2009) Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer. Cancer 115:4080–4089PubMedCrossRefGoogle Scholar
  17. 17.
    Jentzer A (1930) Neurotropisme des cellules cancéreuses: clinique et thérapeutique des cancers neurotropes. Schweiz Med Wochenschr 60:1050–1052Google Scholar
  18. 18.
    Obyama K (1984) Clinicopathologic study on resected cases of carcinoma of the pancreas: prognosis and lymphatic metastasis. Jpn J Surg 85:820–834Google Scholar
  19. 19.
    Chen JW, Bhandari M, Astill DS et al (2010) Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxf) 12:101–108CrossRefGoogle Scholar
  20. 20.
    Shimada K, Nara S, Esaki M et al (2011) Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas. Pancreas 40:464–468PubMedCrossRefGoogle Scholar
  21. 21.
    Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081PubMedCrossRefGoogle Scholar
  22. 22.
    Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825PubMedCrossRefGoogle Scholar
  23. 23.
    Riediger H, Keck T, Wellner U et al (2009) The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 13:1337–1344PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2014

Authors and Affiliations

  • Thibaut Fouquet
    • 1
  • Adeline Germain
    • 1
  • Laurent Brunaud
    • 1
  • Laurent Bresler
    • 1
  • Ahmet Ayav
    • 1
  1. 1.Department of HPB SurgeryUniversity Hospital NancyVandoeuvre les NancyFrance

Personalised recommendations